Matrix-M is a vaccine adjuvant, a substance that is added to various vaccines to stimulate the immune response. [1] [2] [3] It was patented in 2020 by Novavax [4] and is composed of nanoparticles from saponins extracted from Quillaja saponaria (soapbark) trees, …

Novavax develops Matrix adjuvants for both human (Matrix-M) and veterinary (Matrix-V) applications. Matrix adjuvants are produced through a unique process that results in very small, spherical particles that resemble a honeycomb-like structure when …

Dec 31, 2023 · Matrix-M induces early activation of innate immune cells at the injection site and in the draining lymph nodes. This translates into improved magnitude and quality of the antibody response to the antigen, broadened epitope recognition, and the induction of a Th1-dominant immune response.

Oct 2, 2023 · The vaccine contains R21 antigen developed by University of Oxford, specific to the malaria parasite, and Novavax’s Matrix-M, a saponin-based adjuvant that enhances the immune response, making it broader and more durable.

Feb 2, 2024 · The R21/Matrix-M vaccine is one of several ongoing collaborations involving Novavax’s adjuvant technology, including additional research in malaria and other infectious diseases in both humans and animals.

Jun 5, 2023 · When added to vaccines, Novavax's patented saponin-based Matrix-M adjuvant enhances the immune system response, making it broader, and more durable. The Matrix-M adjuvant stimulates the entry of antigen-presenting cells at the injection site and enhances antigen presentation in local lymph nodes.

Dec 20, 2020 · Matrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax. This compound is administered alongside vaccines to enhance biological functions: creating robust and...

Co-formulation with Matrix-M significantly increased HA vaccine immunogenicity, resulting in antigen-specific humoral and cellular immune responses comparable to those induced by unadjuvanted rMVA-HA.

Jul 23, 2012 · Adjuvant Matrix-M™ is comprised of 40 nm nanoparticles composed of Quillaja saponins, cholesterol and phospholipid. BALB/c mice were subcutaneously injected once with, 3, 12 or 30 µg of Matrix-M™, resulting in recruitment of leukocytes to draining lymph nodes (dLNs) and spleen 48 h post treatment.

Matrix-M adjuvant, made of Quillaja saponins formulated with cholesterol and phospholipids into nanoparticles, is known to augment Th1 and Th2 responses, induce antibodies of multiple subclasses, enhance immune cell trafficking, and allow antigen dose-sparing [25–31].